RxDoctor Payments Data

Vincent Matteucci, MD

Ophthalmology · Bellingham, WANPI 1366532897

Payments from drug & device makers

$1,908in general payments, 2019–2025

Across 58 payments — averaging $32.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$449
  • AbbVie$325
  • Biotissue Holdings Inc.$242
  • Ivantis, Inc$163
  • Sun Pharmaceutical Industries Inc.$159
  • Apellis Pharmaceuticals, Inc.$104
  • plus $466 from 11 others

What the payments were for

  • Food & beverage$1,86998%
  • Gifts$392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,908 in reported general payments places this provider in the 65th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$555,643
Medicare patients
1,462
Services billed
5,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast63$61,789
RestasisCyclosporine67$61,076
Cyclosporine51$18,827
Latanoprost453$7,397
CombiganBrimonidine Tartrate/Timolol16$5,995
Brimonidine Tartrate119$5,414
Fluorometholone62$5,093
Prednisolone Acetate91$4,670
Timolol Maleate169$4,178
Brinzolamide12$2,870
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat92$1,750
Ketorolac Tromethamine53$1,529
ErythromycinErythromycin Base86$954
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha76$876
Gatifloxacin15$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$325$67,07183 claims
Bausch & Lomb Americas Inc.Xiidra$53$61,78963 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Bellingham

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →